Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase III | Treatment | Active | 18 and over | Pharmaceutical / Industry | 116513 NCT01597908 |
Summary
This is a two-arm, open-label, randomised, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy to vemurafenib. Subjects with histologically confirmed cutaneous melanoma that is either stage IIIc (unresectable) or stage IV, and BRAF V600E/K mutation positive will be screened for eligibility. Subjects who have had prior systemic anti-cancer treatment in the advanced or metastatic setting will not be eligible although prior systemic treatment in the adjuvant setting will be allowed. Approximately 694 subjects will be randomised 1:1 (combination therapy:vemurafenib). The primary endpoint is overall survival (OS) for subjects receiving the combination therapy compared with those receiving vemurafenib.
Eligibility Criteria
Inclusion Criteria:
- >= 18 years of age
- Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
- Measurable disease according to RECIST 1.1
- Women of childbearing potential with negative serum pregnancy test prior to randomisation
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate baseline organ function
Exclusion Criteria:
- Any prior use of a BRAF or MEK inhibitor
- Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed
- History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)
- Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
- Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisation
- History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
- History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
Trial Lead Organizations/Sponsors
GlaxoSmithkline
| GSK Clinical Trials |  | Study Director |
| US GSK Clinical Trials Call Center | | Ph: 877-379-3718 |
| Email: GSKClinicalSupportHD@gsk.com | ||
Trial Sites
|
|
|
|
| U.S.A. | |||
|
|||
| Alabama | |||
|
|||
| Birmingham | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Arizona | |||
|
|||
| Gilbert | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| California | |||
|
|||
| Beverly Hills | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| San Francisco | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Vallejo | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Colorado | |||
|
|||
| Aurora | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Florida | |||
|
|||
| Jacksonville | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Orlando | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Georgia | |||
|
|||
| Atlanta | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Michigan | |||
|
|||
| Ann Arbor | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Minnesota | |||
|
|||
| Fridley | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Missouri | |||
|
|||
| St. Louis | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nevada | |||
|
|||
| Las Vegas | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| New Jersey | |||
|
|||
| Hackensack | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| New Brunswick | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| North Carolina | |||
|
|||
| Chapel Hill | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Durham | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ohio | |||
|
|||
| Cincinnati | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Columbus | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Oregon | |||
|
|||
| Bend | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Portland | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| South Carolina | |||
|
|||
| Greenville | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Tennessee | |||
|
|||
| Nashville | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Texas | |||
|
|||
| Dallas | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Utah | |||
|
|||
| Salt Lake City | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Vermont | |||
|
|||
| Burlington | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Virginia | |||
|
|||
| Charlottesville | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Wisconsin | |||
|
|||
| Milwaukee | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Argentina | |||
|
|||
| San Miguel de Tucumán | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Santa Fe | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Viedma | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Buenos Aires | |||
|
|||
| Caba | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Capital Federal | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Santa Fe | |||
|
|||
| Rosario | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Australia | |||
|
|||
| Nedlands | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| New South Wales | |||
|
|||
| North Sydney | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Westmead | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Queensland | |||
|
|||
| Greenslopes | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Herston | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| South Brisbane | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| South Australia | |||
|
|||
| Woodville | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Victoria | |||
|
|||
| Melbourne | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Austria | |||
|
|||
| Graz | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Innsbruck | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Salzburg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Wien | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Belgium | |||
|
|||
| Brasschaat | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Brussels | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Gent | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Jette | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Kortrijk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Leuven | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Namur | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Wilrijk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Brazil | |||
|
|||
| Ijui | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Itajaí | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| São Paulo - SP | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Canada | |||
|
|||
| Quebec | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Alberta | |||
|
|||
| Calgary | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| British Columbia | |||
|
|||
| Vancouver | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Manitoba | |||
|
|||
| Winnipeg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nova Scotia | |||
|
|||
| Halifax | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ontario | |||
|
|||
| Kingston | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Oshawa | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ottawa | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Toronto | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Quebec | |||
|
|||
| Montreal | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Czech Republic | |||
|
|||
| Olomouc | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Praha 10 | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Praha 2 | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Zlin | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Denmark | |||
|
|||
| Århus C | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Herlev | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Odense | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Finland | |||
|
|||
| Helsinki | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Jyvaskyla | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Tampere | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Turku | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| France | |||
|
|||
| Bordeaux | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Grenoble | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Lille | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Marseille cedex 5 | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Montpellier cedex 5 | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nantes | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nice | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Paris Cedex 10 | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Reims Cedex | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Rennes Cedex | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Villejuif cedex | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Germany | |||
|
|||
| Bonn | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Buxtehude | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Dresden | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Erfurt | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Essen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Gera | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Hannover | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Heidelberg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Heilbronn | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Kiel | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Koeln | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Leipzig | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ludwigshafen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Luebeck | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Magdeburg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Mainz | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Mannheim | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Muenchen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nuernberg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Regensburg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Tuebingen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Wuerzburg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Hungary | |||
|
|||
| Budapest | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Debrecen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Kaposvár | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Miskolc | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Szeged | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ireland | |||
|
|||
| Co.Cork | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Dublin | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Galway | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Israel | |||
|
|||
| Jerusalem | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ramat Gan | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Italy | |||
|
|||
| Bergamo | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Genova | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Milano | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Napoli | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Padova | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Pisa | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Roma | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Netherlands | |||
|
|||
| Amsterdam | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Groningen | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Leeuwarden | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Leiden | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Rotterdam | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| New Zealand | |||
|
|||
| Christchurch | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Newtown, Wellington | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Norway | |||
|
|||
| Kristiansand | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Oslo | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Poland | |||
|
|||
| Gdansk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Konin | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Poznan | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Warszawa | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Republic of Korea | |||
|
|||
| Goyang-si, Gyeonggi-Do | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Seoul | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Russia | |||
|
|||
| Chelyabinsk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Magnitogorsk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Moscow | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Nizhniy Novgorod | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ryazan | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| St. Petersburg | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Spain | |||
|
|||
| Barcelona | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Hospitalet de Llobregat, Barcelona | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Las Palmas De Gran Canaria | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Madrid | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Palma de Mallorca | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Pamplona | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Valencia | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Sweden | |||
|
|||
| Linköping | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Umeå | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Switzerland | |||
|
|||
| Basel | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Lausanne | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Zürich | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Taiwan | |||
|
|||
| Tainan | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Taipei | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Taoyuan | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Ukraine | |||
|
|||
| Dnipropetrovsk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Donetsk | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Kharkiv | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Kyiv | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Lviv | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Sumy | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Uzhgorod | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| United Kingdom | |||
|
|||
| Cambridge | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Glasgow | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| London | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Manchester | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Southampton | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| Swansea | |||
|
|||
| GSK Investigational Site | |||
| US GSK Clinical Trials Call Center | Ph: 877-379-3718 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
| EU GSK Clinical Trials Call Center | Ph: +44 (0) 20 8990 4466 | ||
| Email: GSKClinicalSupportHD@gsk.com | |||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01597908
Information obtained from ClinicalTrials.gov on June 13, 2013
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
